Clinical Practice Guideline for the Diagnosis and Treatment of Gastroesophageal Reflux Disease (GERD) in Adults: 2025 Update
DOI:
https://doi.org/10.22516/25007440.1450Keywords:
Gastroesophageal Reflux Disease, Clinical Practice Guidelines, Barrett’s EsophagusAbstract
Objective: To provide an evidence-based clinical practice guideline for the diagnosis and treatment of gastroesophageal reflux disease (GERD), addressing the effectiveness and safety of interventions, and aimed at healthcare professionals managing gastrointestinal disorders in any clinical setting in Colombia.
Materials and Methods: This guideline was developed by a multidisciplinary team with support from the Colombian Association of Gastroenterology and Universidad CES. Relevant clinical questions were formulated, and searches were conducted in databases of national and international guidelines. The retrieved guidelines were assessed for quality and applicability; five met criteria for adoption or adaptation. Additional evidence-based documents were considered during drafting. The Universidad CES research group performed a systematic literature review. The GRADE methodology and Evidence-to-Decision (EtD) frameworks were applied, based on guidelines, systematic reviews, and meta-analyses published between 2015 and 2025. Consensus was reached through a multidisciplinary panel, considering applicability, resource availability, and equity within the Colombian healthcare system. The complete methodology and technical appendices are available in the full version at www.gastrocol.com.
Results: A clinical practice guideline was developed for the diagnosis and management of patients with GERD in Colombia, addressing six core clinical questions, with 39 evidence-based recommendations and 18 good practice points. Previous evidence was updated, new recommendations on diagnosis and management were added, and a section dedicated to pregnant patients was included.
Conclusions: This update incorporates new recommendations and establishes a quality standard for the timely diagnosis and management of GERD, contributing to the reduction of disease burden and offering clear criteria for diagnostic evaluation, treatment, and follow-up.
Downloads
References
Zhang D, Liu S, Li Z, Wang R. Global, regional and national burden of gastroesophageal reflux disease, 1990-2019: update from the GBD 2019 study. Ann Med. 54(1):1372-84. https://doi.org/10.1080/07853890.2022.2074535
Tabaeian SP, Moeini S, Rezapour A, Afshari S, Souresrafil A, Barzegar M. Economic evaluation of proton pump inhibitors in patients with gastro-oesophageal reflux disease: a systematic review. BMJ Open Gastroenterol. 2024;11(1):e001465. https://doi.org/10.1136/bmjgast-2024-001465
El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871-80. https://doi.org/10.1136/gutjnl-2012-304269
Salis G. Systematic review: Epidemiology of gastroesophageal reflux disease in Latin America. Acta Gastroenterol Latinoam. 2011;41(1):60-9.
Páramo Hernández DB, Albis R, Galiano MT, Molano BM de, Rincón R, Ovalle LFP, et al. Prevalencia de síntomas del reflujo gastroesofágico y factores asociados: una encuesta poblacional en las principales ciudades de Colombia. Rev Colomb Gastroenterol. 2016;31(4):337-46. https://doi.org/10.22516/25007440.108
Chen Y, Yang K, Marušic A, Qaseem A, Meerpohl JJ, Flottorp S, et al. A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166(2):128-32. https://doi.org/10.1016/j.energy.2016.12.127
Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. J Clin Epidemiol. 2013;66(7):736-742.e5. https://doi.org/10.1016/j.jclinepi.2013.02.004
Ministerio de Salud y Protección Social, IETS. Guía metodológica Adopción - Adaptación de Guías de Práctica Clínica Basadas en Evidencia [Internet]. Ministerio de Salud y Protección Social, IETS; 2017 [consultado el 8 de septiembre de 2025]. Disponible en: https://www.iets.org.co/Archivos/79/Guia_de_Adopcion_VF.pdf
Moayyedi P, Talley NJ, Fennerty MB, Vakil N. Can the Clinical History Distinguish Between Organic and Functional Dyspepsia? JAMA. 2006;295(13):1566-76. https://doi.org/10.1001/jama.295.13.1566
Zhang M, Pandolfino JE, Zhou X, Tan N, Li Y, Chen M, et al. Assessing different diagnostic tests for gastroesophageal reflux disease: a systematic review and network meta-analysis. Ther Adv Gastroenterol. 2019;12:1756284819890537. https://doi.org/10.1177/1756284819890537
Simadibrata DM, Ngadiono E, Sinuraya FAG, Damara I, Fass R, Simadibrata M. Diagnostic accuracy of gastroesophageal reflux disease questionnaire for gastroesophageal reflux disease: A systematic review and meta-analysis. Neurogastroenterol Motil. 2023;35(12). https://doi.org/10.1111/nmo.14619
Ghoneim S, Wang J, El Hage Chehade N, Ganocy SJ, Chitsaz E, Fass R. Diagnostic Accuracy of the Proton Pump Inhibitor Test in Gastroesophageal Reflux Disease and Noncardiac Chest Pain: A Systematic Review and Meta-analysis. J Clin Gastroenterol. 2023;57(4):380-8. https://doi.org/10.1097/MCG.0000000000001686
Olmos JA, Pandolfino JE, Piskorz MM, Zamora N, Díaz MAV, Troche JMR, et al. Latin American consensus on diagnosis of gastroesophageal reflux disease. Neurogastroenterol Motil. 2024;36(3):e14735. https://doi.org/10.1111/nmo.14735
Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900-20. https://doi.org/10.1111/j.1572-0241.2006.00630.x
O’Hara J, Stocken DD, Watson GC, Fouweather T, McGlashan J, MacKenzie K, et al. Use of proton pump inhibitors to treat persistent throat symptoms: multicentre, double blind, randomised, placebo controlled trial. The BMJ. 2021;372:m4903. https://doi.org/10.1136/bmj.m4903
Vaezi MF, Katzka D, Zerbib F. Extraesophageal Symptoms and Diseases Attributed to GERD: Where is the Pendulum Swinging Now? Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2018;16(7):1018-29. https://doi.org/10.1016/j.cgh.2018.02.001
de Bortoli N, Nacci A, Savarino E, Martinucci I, Bellini M, Fattori B, et al. How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related? World J Gastroenterol. 2012;18(32):4363-70. https://doi.org/10.3748/wjg.v18.i32.4363
Metz DC, Childs ML, Ruiz C, Weinstein GS. Pilot study of the oral omeprazole test for reflux laryngitis. Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg. 1997;116(1):41-6. https://doi.org/10.1016/S0194-59989770350-4
Siupsinskiene N, Adamonis K. Diagnostic test with omeprazole in patients with posterior laryngitis. Med Kaunas Lith. 2003;39(1):47-55.
Park W, Hicks DM, Khandwala F, Richter JE, Abelson TI, Milstein C, et al. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response. The Laryngoscope. 2005;115(7):1230-8. https://doi.org/10.1097/01.MLG.0000163746.81766.45
Boys JA, Azadgoli B, Martinez M, Oh DS, Hagen JA, DeMeester SR. Adequacy of EGD Reporting: a Review of 100 Reports from 100 Endoscopists. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2021;25(5):1117-23. https://doi.org/10.1007/s11605-020-04634-2
Suresh Kumar VC, Singh S, Moond V, Pannala SS, Bidani K, Mohan BP, et al. Comparison of the safety, efficacy, and rates of GERD between full-thickness versus modified peroral endoscopic myotomy for achalasia: a systematic review and meta-analysis. Gastrointest Endosc. 2025;S0016-5107(25)01837-1. https://doi.org/10.1016/j.gie.2025.07.017
Dunbar KB, Agoston AT, Odze RD, Huo X, Pham TH, Cipher DJ, et al. Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes. JAMA. 2016;315(19):2104-12. https://doi.org/10.1001/jama.2016.5657
Gyawali CP, Yadlapati R, Fass R, Katzka D, Pandolfino J, Savarino E, et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0. Gut. 2024;73(2):361-71. https://doi.org/10.1136/gutjnl-2023-330616
Katz PO, Dunbar K, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline: Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117(1):27-56. https://doi.org/10.14309/ajg.0000000000001538
Lei WY, Yu HC, Wen SH, Liu TT, Yi CH, Wang CC, et al. Predictive factors of silent reflux in subjects with erosive esophagitis. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2015;47(1):24-9. https://doi.org/10.1016/j.dld.2014.09.017
Visaggi P, Del Corso G, Gyawali CP, Ghisa M, Baiano Svizzero F, Stefani Donati D, et al. Ambulatory pH-Impedance Findings Confirm That Grade B Esophagitis Provides Objective Diagnosis of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2023;118(5):794-801. https://doi.org/10.14309/ajg.0000000000002173
Nikolic M, Matic A, Feka J, Gensthaler L, Kristo I, Osmokrovic B, et al. Expanded Indication for Magnetic Sphincter Augmentation: Outcomes in Weakly Acidic Reflux Compared to Standard GERD Patients. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2022;26(3):532-41. https://doi.org/10.1007/s11605-021-05152-5
Horton AJ, Clayton SB. Optimization of impedance-measured reflux events in GORD utilizing acid exposure time. BMC Gastroenterol. 2020;20(1):179. https://doi.org/10.1186/s12876-020-01321-z
Bredenoord AJ, Weusten BLAM, Timmer R, Conchillo JM, Smout AJPM. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. Am J Gastroenterol. 2006;101(3):453-9. https://doi.org/10.1111/j.1572-0241.2006.00427.x
Zerbib F, Bredenoord AJ, Fass R, Kahrilas PJ, Roman S, Savarino E, et al. ESNM/ANMS consensus paper: Diagnosis and management of refractory gastro-esophageal reflux disease. Neurogastroenterol Motil. 2021;33(4):e14075. https://doi.org/10.1111/nmo.14075
Nakagawa K, Sawada A, Hoshikawa Y, Nikaki K, Sonmez S, Woodland P, et al. Persistent Postprandial Regurgitation vs Rumination in Patients With Refractory Gastroesophageal Reflux Disease Symptoms: Identification of a Distinct Rumination Pattern Using Ambulatory Impedance-pH Monitoring. Am J Gastroenterol. 2019;114(8):1248-55. https://doi.org/10.14309/ajg.0000000000000295
Halland M, Pandolfino J, Barba E. Diagnosis and Treatment of Rumination Syndrome. Clin Gastroenterol Hepatol. 2018;16(10):1549-55. https://doi.org/10.1016/j.cgh.2018.05.049
Hemmink GJM, Bredenoord AJ, Weusten BLAM, Timmer R, Smout AJPM. Supragastric belching in patients with reflux symptoms. Am J Gastroenterol. agosto de 2009;104(8):1992-7. https://doi.org/10.1038/ajg.2009.203
Johnston BT, Troshinsky MB, Castell JA, Castell DO. Comparison of barium radiology with esophageal pH monitoring in the diagnosis of gastroesophageal reflux disease. Am J Gastroenterol. 1996;91(6):1181-5.
Serna-Gallegos D, Basseri B, Bairamian V, Pimentel M, Soukiasian HJ. Gastroesophageal reflux reported on esophagram does not correlate with pH monitoring and high-resolution esophageal manometry. Am Surg. 2014;80(10):1026-9. https://doi.org/10.1177/000313481408001025
Bhardwaj R, Davis TA, Franz A, Kem D, Edds S, Rogers B, et al. Reflux Seen on a Barium Swallow is Not a Substitute For Ambulatory Reflux Monitoring in Symptomatic Patients. J Clin Gastroenterol. 2025. https://doi.org/10.1097/MCG.0000000000002133
Moraes-Filho JPP, Domingues G, Chinzon D. Brazilian clinical guideline for the therapeutic management of gastroesophageal reflux disease (Brazilian Federation Of Gastroenterology, FBG). Arq Gastroenterol. 2024;61:e23154. https://doi.org/10.1590/s0004-2803.24612023-154
Reimer C, Lødrup AB, Smith G, Wilkinson J, Bytzer P. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment Pharmacol Ther. 2016;43(8):899-909. https://doi.org/10.1111/apt.13567
Kim JH, Lee YC, Kim EH, Park JC, Shin SK, Lee SK, et al. The Clinical Efficacy of a Pure Alginate Formulation (Lamina G) for Controlling Symptoms in Individuals with Reflux Symptoms: A Randomized Clinical Study. Gut Liver. 2019;13(6):642-8. https://doi.org/10.5009/gnl18378
Thomas E, Wade A, Crawford G, Jenner B, Levinson N, Wilkinson J. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2014;39(6):595-602. https://doi.org/10.1111/apt.12640
Zhang C, Kwong JSW, Yuan RX, Chen H, Xu C, Wang YP, et al. Effectiveness and Tolerability of Different Recommended Doses of PPIs and H2RAs in GERD: Network Meta-Analysis and GRADE system. Sci Rep. 2017;7:41021. https://doi.org/10.1038/srep41021
Kang SJ, Jung HK, Tae CH, Kim SY, Lee KJ. On-demand Versus Continuous Maintenance Treatment of Gastroesophageal Reflux Disease With Proton Pump Inhibitors: A Systematic Review and Meta-analysis. J Neurogastroenterol Motil. 2022;28(1):5-14. https://doi.org/10.5056/jnm21095
Gralnek IM, Dulai GS, Fennerty MB, Spiegel BMR. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4(12):1452-8. https://doi.org/10.1016/j.cgh.2006.09.013
Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14(10):1267-72. https://doi.org/10.1046/j.1365-2036.2000.00829.x
Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, et al. Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. Expert Rev Clin Pharmacol. 2020;13(4):437-49. https://doi.org/10.1080/17512433.2020.1752664
Eusebi LH, Telese A, Cirota GG, Haidry R, Zagari RM, Bazzoli F, et al. Effect of gastro‐esophageal reflux symptoms on the risk of Barrett’s esophagus: A systematic review and meta‐analysis. J Gastroenterol Hepatol. 2022;37(8):1507-16. https://doi.org/10.1111/jgh.15902
Saha B, Vantanasiri K, Mohan BP, Goyal R, Garg N, Gerberi D, et al. Prevalence of Barrett’s Esophagus and Adenocarcinoma With and Without Gastroesophageal Reflux: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2024;22(7):1381-1394.e7. https://doi.org/10.1016/j.cgh.2023.10.006
Megwalu UC. A systematic review of proton-pump inhibitor therapy for laryngopharyngeal reflux. Ear Nose Throat J. 2013;92(8):364-71. https://doi.org/10.1177/014556131309200811
Qadeer MA, Phillips CO, Lopez AR, Steward DL, Noordzij JP, Wo JM, et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006;101(11):2646-54. https://doi.org/10.1111/j.1572-0241.2006.00844.x
Lechien JR, Saussez S, Schindler A, Karkos PD, Hamdan AL, Harmegnies B, et al. Clinical outcomes of laryngopharyngeal reflux treatment: A systematic review and meta-analysis. The Laryngoscope. 2019;129(5):1174-87. https://doi.org/10.1002/lary.27591
Guo H, Ma H, Wang J. Proton Pump Inhibitor Therapy for the Treatment of Laryngopharyngeal Reflux: A Meta-Analysis of Randomized Controlled Trials. J Clin Gastroenterol. 2016;50(4):295-300. https://doi.org/10.1097/MCG.0000000000000324
Karkos PD, Wilson JA. Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review. The Laryngoscope. 2006;116(1):144-8. https://doi.org/10.1097/01.mlg.0000191463.67692.36
Cho YK, Choi MG, Park H, Kim JW, Lee DH, Ko KH, et al. Efficacy of S-pantoprazole 10 mg in the Symptom Control of Non-erosive Reflux Disease: A Phase III Placebo-controlled Trial. J Neurogastroenterol Motil. 2021;27(2):223-30. https://doi.org/10.5056/jnm19053
Peura DA, Le Moigne A, Wassel H, Pollack C. Sustained efficacy following resolution of frequent heartburn with an over-the-counter regimen of esomeprazole 20 mg or placebo for 14 days: two randomized trials. BMC Gastroenterol. 2018;18:69. https://doi.org/10.1186/s12876-018-0790-2
Katz PO, Le Moigne A, Pollack C. Analysis of 2-Week Data from Two Randomized, Controlled Trials Conducted in Subjects with Frequent Heartburn Treated with Esomeprazole 20 mg. Clin Ther. 2017;39(5):960-70. https://doi.org/10.1016/j.clinthera.2017.03.015
Tan VPY, Wong WM, Cheung TK, Lai KC, Hung IFN, Chan P, et al. Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial. J Gastroenterol. 2011;46(7):906-12. https://doi.org/10.1007/s00535-011-0402-1
Zheng RN. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World J Gastroenterol. 2009;15(8):990-5. https://doi.org/10.3748/wjg.15.990
Graham DY, Tansel A. Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2018;16(6):800-808.e7. https://doi.org/10.1016/j.cgh.2017.09.033
Lee RD, Mulford D, Wu J, Atkinson SN. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor. Aliment Pharmacol Ther. 2010;31(9):1001-11. https://doi.org/10.1111/j.1365-2036.2010.04272.x
Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019;157(3):682-691.e2.
Castellana C, Pecere S, Furnari M, Telese A, Matteo MV, Haidry R, et al. Side effects of long-term use of proton pump inhibitors: practical considerations. Pol Arch Intern Med. 2021;131(6):541-9. https://doi.org/10.20452/pamw.15997
Srinutta T, Chewcharat A, Takkavatakarn K, Praditpornsilpa K, Eiam-Ong S, Jaber BL, et al. Proton pump inhibitors and hypomagnesemia: A meta-analysis of observational studies. Medicine (Baltimore). 2019;98(44):e17788. https://doi.org/10.1097/MD.0000000000017788
Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;2013(5):CD002095. https://doi.org/10.1002/14651858.CD002095.pub5
Modlin IM, Hunt RH, Malfertheiner P, Moayyedi P, Quigley EM, Tytgat GNJ, et al. Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group. Digestion. 2009;80(2):74-88. https://doi.org/10.1159/000219365
Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54(5):710-7. https://doi.org/10.1136/gut.2004.051821
Kinoshita Y, Sakurai Y, Shiino M, Kudou K, Nishimura A, Miyagi T, et al. Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Curr Ther Res Clin Exp. 2016;81-82:1-7. https://doi.org/10.1016/j.curtheres.2016.12.001
Xiao Y, Zhang S, Dai N, Fei G, Goh KL, Chun HJ, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 2020;69(2):224-30. https://doi.org/10.1136/gutjnl-2019-318365
Sakurai K, Suda H, Fujie S, Takeichi T, Okuda A, Murao T, et al. Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan. Dig Dis Sci. 2019;64(3):815-22. https://doi.org/10.1007/s10620-018-5365-0
Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43(2):240-51. https://doi.org/10.1111/apt.13461
Kinoshita Y, Sakurai Y, Takabayashi N, Kudou K, Araki T, Miyagi T, et al. Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study. Clin Transl Gastroenterol. 2019;10(11):e00101. https://doi.org/10.14309/ctg.0000000000000101
Cheng Y, Liu J, Tan X, Dai Y, Xie C, Li X, et al. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2021;66(1):19-28. https://doi.org/10.1007/s10620-020-06141-5
Chandan S, Deliwala S, Mohan BP, Ramai D, Dhindsa B, Bapaye J, et al. Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials. Indian J Gastroenterol Off J Indian Soc Gastroenterol. 2023;42(4):475-84. https://doi.org/10.1007/s12664-023-01384-2
Zamani NF, Sjahid AS, Tuan Kamauzaman TH, Lee YY, Islam MA. Efficacy and Safety of Domperidone in Combination with Proton Pump Inhibitors in Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. J Clin Med. 2022;11(18):5268. https://doi.org/10.3390/jcm11185268
Spechler SJ, Hunter JG, Jones KM, Lee R, Smith BR, Mashimo H, et al. Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. N Engl J Med. 2019;381(16):1513-23. https://doi.org/10.1056/NEJMoa1811424
Iwakiri K, Sakurai Y, Shiino M, Okamoto H, Kudou K, Nishimura A, et al. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Ther Adv Gastroenterol. 2017;10(6):439-51. https://doi.org/10.1177/1756283X17705329
Mizuki A, Tatemichi M, Sakakibara T, Miura Y, Zeki S, Ohata M, et al. A Multicenter, Randomized, Open-Label Trial: Efficacy of Once-Daily Versus Twice-Daily Double-Dose Rabeprazole on Refractory Gastroesophageal Reflux Disease-Related Symptoms and Quality of Life. Curr Ther Res Clin Exp. 2016;79:1-7. https://doi.org/10.1016/j.curtheres.2016.11.002
Fass R, Murthy U, Hayden CW, Malagon IB, Pulliam G, Wendel C, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther. 2000;14(12):1595-603. https://doi.org/10.1046/j.1365-2036.2000.00882.x
Rivière P, Vauquelin B, Rolland E, Melchior C, Roman S, Bruley des Varannes S, et al. Low FODMAPs diet or usual dietary advice for the treatment of refractory gastroesophageal reflux disease: An open-labeled randomized trial. Neurogastroenterol Motil. 2021;33(9):e14181. https://doi.org/10.1111/nmo.14181
Pauwels A, Raymenants K, Geeraerts A, Boecxstaens V, Masuy I, Broers C, et al. Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms. Aliment Pharmacol Ther. 2022;56(2):231-9. https://doi.org/10.1111/apt.17068
Chen J, Dong P, Chen S, Zhuang Q, Zhang M, Sun K, et al. The Los Angeles-B esophagitis is a conclusive diagnostic evidence for gastroesophageal reflux disease: the validation of Lyon Consensus 2.0. Gastroenterol Rep. 2025;13:goaf004. https://doi.org/10.1093/gastro/goaf004
Mathus-Vliegen EMH, van Weeren M, van Eerten PV. Loss function and obesity: the impact of untreated obesity, weight loss, and chronic gastric balloon distension. Digestion. 2003;68(2-3):161-8. https://doi.org/10.1159/000075525
Mathus-Vliegen EMH, Tygat GNJ. Gastro-oesophageal reflux in obese subjects: influence of overweight, weight loss and chronic gastric balloon distension. Scand J Gastroenterol. 2002;37(11):1246-52. https://doi.org/10.1080/003655202761020498
Mathus-Vliegen LM, Tytgat GN. Twenty-four-hour pH measurements in morbid obesity: effects of massive overweight, weight loss and gastric distension. Eur J Gastroenterol Hepatol. 1996;8(7):635-40.
Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut. 2014;63(8):1229-37. https://doi.org/10.1136/gutjnl-2013-305997
Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study. Am J Gastroenterol. 2013;108(3):376-82. https://doi.org/10.1038/ajg.2012.466
Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006;354(22):2340-8. https://doi.org/10.1056/NEJMoa054391
Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Tobacco smoking cessation and improved gastroesophageal reflux: a prospective population-based cohort study: the HUNT study. Am J Gastroenterol. 2014;109(2):171-7. https://doi.org/10.1038/ajg.2013.414
Kohata Y, Fujiwara Y, Watanabe T, Kobayashi M, Takemoto Y, Kamata N, et al. Long-Term Benefits of Smoking Cessation on Gastroesophageal Reflux Disease and Health-Related Quality of Life. Plos One. 2016;11(2):e0147860. https://doi.org/10.1371/journal.pone.0147860
Desai M, Ruan W, Thosani NC, Amaris M, Scott JS, Saeed A, et al. American Society for Gastrointestinal Endoscopy guideline on the diagnosis and management of GERD: summary and recommendations. Gastrointest Endosc. 2025;101(2):267-84. https://doi.org/10.1016/j.gie.2024.10.008
Piesman M, Hwang I, Maydonovitch C, Wong RKH. Nocturnal reflux episodes following the administration of a standardized meal. Does timing matter? Am J Gastroenterol. 2007;102(10):2128-34. https://doi.org/10.1111/j.1572-0241.2007.01348.x
Qumseya BJ, Qumsiyeh Y, Ponniah SA, Estores D, Yang D, Johnson-Mann CN, et al. Barrett’s esophagus after sleeve gastrectomy: a systematic review and meta-analysis. Gastrointest Endosc. 2021;93(2):343-352.e2. https://doi.org/10.1016/j.gie.2020.08.008
Muthusamy VR, Lightdale JR, Acosta RD, Chandrasekhara V, Chathadi KV, Eloubeidi MA, et al. The role of endoscopy in the management of GERD. Gastrointest Endosc. 2015;81(6):1305-10. https://doi.org/10.1016/j.gie.2015.02.021
Qumseya B, Sultan S, Bain P, Jamil L, Jacobson B, Anandasabapathy S, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc. 2019;90(3):335-359.e2. https://doi.org/10.1016/j.gie.2019.05.012
Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med. 2004;140(7):518-27. https://doi.org/10.7326/0003-4819-140-7-200404060-00011
Lechien JR, Schindler A, De Marrez LG, Hamdan AL, Karkos PD, Harmegnies B, et al. Instruments evaluating the clinical findings of laryngopharyngeal reflux: A systematic review. The Laryngoscope. 2019;129(3):720-36. https://doi.org/10.1002/lary.27537
Iqbal M, Batch AJ, Spychal RT, Cooper BT. Outcome of surgical fundoplication for extraesophageal (atypical) manifestations of gastroesophageal reflux disease in adults: a systematic review. J Laparoendosc Adv Surg Tech A. 2008;18(6):789-96. https://doi.org/10.1089/lap.2007.0165
Sidwa F, Moore AL, Alligood E, Fisichella PM. Surgical Treatment of Extraesophageal Manifestations of Gastroesophageal Reflux Disease. World J Surg. 2017;41(10):2566-71. https://doi.org/10.1007/s00268-017-4058-8
Altuwaijri M. Evidence-based treatment recommendations for gastroesophageal reflux disease during pregnancy: A review. Medicine (Baltimore). 2022;101(35):e30487. https://doi.org/10.1097/MD.0000000000030487
Valdovinos-Díaz MA, Hani A, Defilippi-Guerra C, Fernando-Pineda L, Remes-Troche JM, Riquelme A, et al. Recomendaciones de buena práctica clínica para el manejo de la enfermedad por reflujo gastroesofágico. Revisión por expertos latinoamericanos. Rev Gastroenterol México. 2025;90(2):288-308. https://doi.org/10.1016/j.rgmx.2025.02.001
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Revista colombiana de Gastroenterología
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
